News | March 30, 2009

Long-Term Data Demonstrates Safety, Efficacy of OPTIMIZER System

March 30, 2009 - Impulse Dynamics announced findings from the FIX-HF-5 study of its OPTIMIZER System at the 58th Annual Scientific Session of the American College of Cardiology in Orlando, FL, demonstrating positive longer term effects of the system’s cardiac contractility modulation (CCM) signals.

The OPTIMIZER System consists of a pulse generator and conventional pacing leads which deliver the therapy to the cardiac tissue. The device is implanted in a manner similar to a pacemaker procedure. Unlike conventional pacing methods, however, the OPTIMIZER device utilizes CCM therapy in which electrical impulses are delivered to the heart after the heart has already initiated its contraction. CCM is designed to increase the forcefulness of the heart's pumping action rather than initiating a new contraction.

The FIX-HF-5 study met its primary safety endpoint, which was a non-inferiority demonstration of the composite of all-cause mortality and all-cause hospitalizations. Compared to the control group, patients treated with CCM signals over the other group had significantly improved exercise tolerance as judged by an increase in peak oxygen update (p=0.02) and an improvement in quality of life as judged by a reduction in the Minnesota Living with Heart Failure score (p

"We are pleased to report these longer term data that add to the growing wealth of knowledge showing the potential of CCM as a therapy for heart failure patients with no other options," said Dr. William Abraham, professor of internal medicine and director of the Division of Cardiovascular Medicine, Ohio State University Medical Center.

In a subgroup representing the "less sick" half of the study population (NYHA Class III with ejection fraction 25% and above), the study found even greater improvements not only in peak VO2 (p=0.001) and quality of life (p=0.003), but also in the primary endpoint of ventilatory anaerobic threshold (p=0.03). These effects were largely maintained at twelve months as well.

"This subgroup of the less severely impaired patients appeared to demonstrate an overall greater response rate that those in the control group," noted Dr. Alan Kadish, professor, Division of Cardiology, Feinberg School of Medicine, Northwestern University. "We are particularly encouraged by the findings in this subgroup of patients and look forward to focusing on this subgroup in our next study."

The OPTIMIZER System is CE Marked and commercially available in Europe and is currently under clinical investigation at major U.S. research and academic facilities.

For more information: www.impulse-dynamics.com.

Related Content

HRS study finds Frequent Coffee Consumption Lowers Chance of Arrhythmias. #HRS #HRS20 Heartrhythm20
News | EP Lab | May 28, 2020
May 28, 2020 – A recent study revealed that drinking a couple of cups of coffee per day does not lead to a greater ri
he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

News | EP Lab | May 20, 2020
May 20, 2020 — Acutus Medical and Biotronik announced a new alliance to provide a comprehensive portfolio of...
Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter.
News | EP Lab | May 19, 2020
May 19, 2020 – Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), an
HRS presentations included BlueSync Evaluation study for Medtronic MyCareLink Heart mobile app and Micra TPS CED Study
News | EP Lab | May 14, 2020
May 14, 2020 – Medtronic announced results from late-breaking clinical trials evaluating the MyCareLink Heart mobile
Etripamil Nasal Spray Does Not Meet Primary Endpoint in Treating Supraventricular Tachycardia in the NODE-301 trial presented at Heart Rhythm 2020. #heartrhythm2020 #HRS2020
News | EP Lab | May 13, 2020
May 13, 2020 — The patient-administered nasal spray drug etripamil did not meet its primary endpoint in treating pati
Medtronic Cobalt and Crome ICD
News | EP Lab | May 12, 2020
May 12, 2020 — Medtronic has received FDA approval for its Cobalt and Crome implantable cardioverter-defibrillators (
The CardioFocus HeartLight Excalibur Balloon X3 ablation system allows direct visualization of the laser ablation procedure, helping reduce use of X-ray angiography and reducing procedure time. FDA clears, approved, the HeartLight X3 Laser Ablation System to Treat Atrial Fibrillation.

The CardioFocus HeartLight Excalibur Balloon X3 ablation system allows direct visualization of the laser ablation procedure, helping reduce use of X-ray angiography and reducing procedure time.

News | EP Lab | May 12, 2020
May 12, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the next-generation CardioFocus Inc.
EP lab photo from Philips Healthcare
News | EP Lab | April 30, 2020
May 1, 2020 — The Heart Rhythm Society (HRS) has created a COVID-19 Task Force to make recommendations related to edu
The European Heart Rhythm Association (EHRA) electrophysiology (EP) annual meeting cancelled due to coronavirus. #COVID19 #coronavirus #2019nCoV
Feature | EP Lab | March 10, 2020 | Dave Fornell, Editor
March 10, 2020 — Novel coronavirus (...
The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical SuperMap, an addition to its AcQMap 3-D imaging and mapping system used to guide electrophysiology (EP) catheter ablation procedures. Adding the SuperMap mode to the AcQMap system enables users to visualize any atrial rhythm in less than three minutes. Rapidly mapping and re-mapping the whole heart chamber facilitates a new procedural workflow in EP ablation, making it practical to execute an iterative "map, ablate, re-map" approach.
News | EP Lab | March 05, 2020
March 5, 2020 — The U.S.